Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate
09. Februar 2021 07:00 ET
|
Melt Pharmaceuticals; Harrow Health, Inc.
BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for sedation and analgesia, announced results from...
Melt Pharmaceuticals Enters the Clinical Stage of MELT-100 Development
29. Juli 2020 07:00 ET
|
Melt Pharmaceuticals
FDA has accepted MELT-100 IND; Phase 1 study enrollment to start immediately BOSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing...